Stockchase Opinions

David Driscoll Novo-Nordisk NVO-N BUY ON WEAKNESS Mar 25, 2025

Is -17% this year and -42% the past year. It went too far too fast. He's been buying more on the way down, because obesity won't change, so their weight-loss drug will keep selling. Tariffs: NVO has facilities in the US already. 60% of revenues are outside North America (vs. Eli Lilly's 60% within US). To extend patent protection, a pharma company just needs to change its formula every 3 years to extend the patent protection. There will be competition, but NVO has brand recognition and scale.

$73.600

Stock price when the opinion was issued

biotechnology pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

TOP PICK

It is the largest player in obesity drugs which includes Ozempic. A large percentage of the population in North America are overweight and this condition causes chronic diseases. Therefore obesity drugs help to bring down costs to treat these chronic diseases. The stock price  has fallen because of an over-reaction to an announcement. It is a great franchise and has other businesses. The NOVO foundation owns the majority of shares and can't be taken over.         Buy 7  Hold 4  Sell 1

(Analysts’ price target is $110.23)
BUY

Has owned this a long time, but has trimmed recently. Unfortunately, diabetes is a growing business. Stocks have fallen recently, because supply couldn't meet demand, but the price is attractive and reasonable.

DON'T BUY

So many companies now with competing weight-loss products. Riding the hype on this one drug, and he'd much prefer more diversification.

PAST TOP PICK
(A Top Pick Mar 26/24, Down 41%)

Sentiment's pretty rough on this name. Fairly cheap at 22x forward PE, 18% earnings growth. Regulatory scrutiny. Lost a bit of market share to LLY (which he still holds). Below 200-day MA, which is moving down. Growth of GLP-1 drugs is there, so he's keeping an eye on it for future.

HOLD
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research

Its stock decline is not unique in this market: most growth companies have been hit very very hard, in one of the sharpest sell-offs we have seen in some time. NVO is 19X earnings now, with a 2.90% dividend. The balance sheet is fine and good growth is still expected over the next two years. We would be comfortable owning this and riding out the current market malaise, which will end one of these days (weeks, or months).
Unlock Premium - Try 5i Free

DON'T BUY

Now a whole slew of competitors in the weight-loss space. He'd prefer a more diversified pharma company.

PAST TOP PICK
(A Top Pick Mar 06/24, Down 51%)

He's out. Valuation has now become fairly attractive at 16x forward PE for 14-15% growth. Below 200-week MA, troubling. Long term, a name to look at again once things turn around. Losing some market share to LLY.

BUY ON WEAKNESS

He prefers Eli Lilly, but shares of NVO have come down enough.

PAST TOP PICK
(A Top Pick Apr 10/24, Down 51%)

Overvalued to start with, and expectations were high. Small miss on weight loss percentage led to huge drop in stock price. LLY is grabbing more market share. Worry that drugs in US will face tariffs. Buy here, do well in the long run.